Conclusion
®
Exploring ETVAX® for the first time in a large traveller population, the present investigation finds this vaccine to be safe and well tolerated, showing no significant differences in AEs between vaccine and placebo recipients. The study also demonstrates ETVAX® to be highly immunogenic in a traveller population, inducing robust antibacterial and antitoxin immune responses.